http://investor.enzon.com/releases.cfm?sh_auth=0.0.0.ad1dcb691ef81696c0c02ea27e385165en-usShareholder.com RSS Feedhttp://investor.enzon.com/releasedetail.cfm?ReleaseID=758565Tue, 23 Apr 2013 20:01:00 GMThttp://investor.enzon.com/releasedetail.cfm?ReleaseID=758565Enzon Concludes Review of Possible Asset Sales, Sale of the Company; Announces $1.60 Special Dividend and Periodic Royalty Dividendshttp://investor.enzon.com/releasedetail.cfm?ReleaseID=749289Mon, 18 Mar 2013 21:07:00 GMThttp://investor.enzon.com/releasedetail.cfm?ReleaseID=749289Enzon Reports Fourth Quarter and Full Year 2012 Resultshttp://investor.enzon.com/releasedetail.cfm?ReleaseID=727147Mon, 17 Dec 2012 12:00:00 GMThttp://investor.enzon.com/releasedetail.cfm?ReleaseID=727147Enzon to Review Asset Sales, Sale of the Companyhttp://investor.enzon.com/releasedetail.cfm?ReleaseID=724138Thu, 29 Nov 2012 22:27:00 GMThttp://investor.enzon.com/releasedetail.cfm?ReleaseID=724138Enzon Announces Special Dividendhttp://investor.enzon.com/releasedetail.cfm?ReleaseID=719684Thu, 08 Nov 2012 13:00:00 GMThttp://investor.enzon.com/releasedetail.cfm?ReleaseID=719684Enzon Announces Two Oral Presentations at the Symposium of Drug Delivery Systems in Nanjing, Chinahttp://investor.enzon.com/releasedetail.cfm?ReleaseID=717411Wed, 31 Oct 2012 11:00:00 GMThttp://investor.enzon.com/releasedetail.cfm?ReleaseID=717411Enzon Reports Third Quarter 2012 Resultshttp://investor.enzon.com/releasedetail.cfm?ReleaseID=706256Tue, 11 Sep 2012 15:10:00 GMThttp://investor.enzon.com/releasedetail.cfm?ReleaseID=706256Enzon to Present at 2012 World Congress and Expo on Biowaivers and Biosimilarshttp://investor.enzon.com/releasedetail.cfm?ReleaseID=697148Wed, 01 Aug 2012 11:00:00 GMThttp://investor.enzon.com/releasedetail.cfm?ReleaseID=697148Enzon Reports Second Quarter 2012 Resultshttp://investor.enzon.com/releasedetail.cfm?ReleaseID=692106Mon, 16 Jul 2012 13:30:00 GMThttp://investor.enzon.com/releasedetail.cfm?ReleaseID=692106Enzon Presents Pre-Clinical Data on Controlled Release of PEGylated Interferon-Beta-1b and PEGylated anti-TNF-a Antibody Fragment at the Controlled Release Society Annual Meetinghttp://investor.enzon.com/releasedetail.cfm?ReleaseID=684289Tue, 19 Jun 2012 16:30:00 GMThttp://investor.enzon.com/releasedetail.cfm?ReleaseID=684289Enzon Announces Data From Phase I Study of PEG-SN38 in Pediatric Neuroblastoma and Other Solid Tumors Presented at 2012 Advances in Neuroblastoma Research Conference